BOLT Form 4: CEO awarded 40,000 RSUs; 42,188 shares owned

Bolt Biotherapeutics (BOLT) disclosed insider equity activity by its President, CEO and CFO, William P. Quinn.

Rhea-AI Filing Summary

Bolt Biotherapeutics (BOLT) disclosed insider equity activity by its President, CEO and CFO, William P. Quinn. On 10/22/2025, he acquired 40,000 restricted stock units (RSUs) for $0. Each RSU represents one share of common stock at settlement, and the award vests in full on September 15, 2026, assuming continued employment.

Earlier, on 06/06/2025, Quinn purchased 125 shares of common stock at $5.492 per share under the company’s Employee Stock Purchase Plan, which is exempt under Rule 16b-3(c). After the reported transactions, he beneficially owned 42,188 shares directly.

Insider Trade Summary

Net Buyer: 125 shares

Net Buy 2 txns

Insider Quinn William P.

Role President, CEO and CFO

Bought 125 shs ($686.50)

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	40,000	$0.00	$0.00
Purchase	Common Stock	125	$5.492	$686.50

Holdings After Transaction: Common Stock — 42,188 shares (Direct)

Footnotes (3)

1. F1. Shares acquired under the issuer's Employee Stock Purchase Plan and therefore exempt under Rule 16b-3(c)
2. F2. The shares represent restricted stock units that were received as an award, for no consideration. Each restricted stock unit represents the right to receive, at settlement, one share of common stock.
3. F3. The restricted stock units subject to the award will vest in full on September 15, 2026, assuming continued employment through such date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did BOLT report on this Form 4?

William P. Quinn acquired 40,000 RSUs on 10/22/2025 for $0, and previously bought 125 shares at $5.492 on 06/06/2025.

When do the newly granted BOLT RSUs vest?

The 40,000 RSUs vest in full on September 15, 2026, assuming continued employment.

How many BOLT shares does the reporting person own after these transactions?

Following the transactions, William P. Quinn beneficially owned 42,188 shares directly.

What is the price associated with the RSU grant reported by BOLT?

The RSUs were received for $0 consideration; each RSU represents one share at settlement.

What was the price paid for shares purchased under BOLT’s ESPP?

On 06/06/2025, 125 shares were purchased at $5.492 per share under the ESPP.

Who is the reporting person and what is their role at BOLT?

The reporting person is William P. Quinn, who serves as President, CEO and CFO, and is also a Director.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 10/24/2025 - 07:18 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Quinn William P.

(Last) (First) (Middle)

C/O BOLT BIOTHERAPEUTICS, INC.

900 CHESAPEAKE DRIVE

(Street)

REDWOOD CITY CA 94063

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Bolt Biotherapeutics, Inc. [ BOLT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President, CEO and CFO

3. Date of Earliest Transaction (Month/Day/Year)
10/24/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/06/2025		P		125(1)	A	$5.492	2,188	D
Common Stock	10/22/2025(2)	(3)	A		40,000	A	$0(2)	42,188	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares acquired under the issuer's Employee Stock Purchase Plan and therefore exempt under Rule 16b-3(c)

2. The shares represent restricted stock units that were received as an award, for no consideration. Each restricted stock unit represents the right to receive, at settlement, one share of common stock.

3. The restricted stock units subject to the award will vest in full on September 15, 2026, assuming continued employment through such date.

	/s/ William P. Quinn	10/24/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.